Therefore, we evaluated WT1 antigen-specific CTLs (WT1-CTLs) using the IFN-γ ELISpot assay in comparison with the MHC tetramer analysis as a validation method of DC-based cancer immunotherapy. The gene discussed is IFNG; the disease is cancer.